Rigel Pharma (RIGL) Misses Q1 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts RIGL Hot Sheet
Price: $48.13 -1.49%
Revenue Growth %: +15.2%
Financial Fact:
General and administrative: 4.56M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Revenue Growth %: +15.2%
Financial Fact:
General and administrative: 4.56M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) reported Q1 EPS of ($0.40), $0.04 worse than the analyst estimate of ($0.36).
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Rigel to present pralsetinib cancer data at ESMO Congress 2026
- Boston Beer Co. (SAM) Tops Q3 EPS by 15c; offers guidance
- Booz Allen Hamilton (BAH) Tops Q2 EPS by 28c, Misses on Revenue
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
